TG Therapeutics (TGTX) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

TG Therapeutics

NasdaqCM•Healthcare•Biotechnology

$55.85+2.81(0.05%)Pre-market

Market Cap

$8.01B

P/E

18.1x

P/S

10.0x

P/B

13.3x

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina.

How this company scores

GoodMetricSide Score: 64/100

Strongest: Growth (25/25); weakest: Balance Sheet & Red Flags (7/25).

Profitability22/25

Growth25/25

Balance Sheet & Red Flags7/25

Cash & Earnings Quality10/25

Strengths

Growing revenueStrong marginsHigh ROERising earnings

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 18.1x5y range 9.2x – 195.3x

Currently below its 10-quarter median.

P/S · 10.0x5y range 6.3x – 1008.4x

Currently near its 20-quarter median.

P/B · 13.3x5y range 4.5x – 84.3x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Watch

Operating margins declined 5.3% — watch for continued compression, which may signal competitive or cost pressure.

Earnings Quality

Red Flag

Free cash flow has been negative in 5 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $8.01B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $799.54M
Q. Revenue: $240.34M
TTM EBITDA: $136.45M
TTM Op. Income: $136.33M
Q. Op. Income: $21.67M
TTM Net Income: $441.49M
Q. Net Income: $7.78M
EPS: $0.05
Shares Out.: $141.77M

$799.54M in TTM revenue grew 76.1% YoY, reaching $240.34M last quarter. TTM EBITDA of $136.45M and TTM operating income of $136.33M show growth is flowing through to the bottom line. TTM net income of $441.49M means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 7 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 82.9%
EBITDA Margin: 9.0%
Op. Margin: 9.0%
Net Margin: 3.2%

Op. margin of 9.0% is down 15.7% YoY — costs are rising relative to revenue. Net margin at 3.2% and gross margin of 82.9% show how much of each revenue dollar survives to profit. Across the last 8 quarters, operating margin has fallen for 2 consecutive quarters — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 18.1x
P/S Ratio: 10.0x
P/B Ratio: 13.3x

At 18.1x P/E, the stock trades within typical market levels. P/S of 10.0x and P/B of 13.3x provide additional context. Use the growth and margin sections to judge whether the multiple is justified. Across the last 7 quarters, P/E has risen for 2 consecutive quarters — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $1.64B
Cash: $482.57M
Long-Term Debt: $745.39M
Book Value: $604.08M
D/E Ratio: 1.2
Debt/EBITDA: 34.3

With $1.64B in assets and $745.39M in long-term debt, D/E is 1.2and book value is $604.08M — moderate leverage. Over the past year, debt/equity is up 39% — an improving trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $39.26M
TTM Free Cash Flow: $17.39M
FCF Margin: 2.2%
FCF / Net Income: 0.0

TTM FCF of $17.39M on $39.26M in operating cash flow. The FCF / Net Income ratio of 0.0x means cash covers only part of net income — earnings quality needs attention. Across the last 8 quarters, free cash flow has risen for 3 consecutive quarters — an improving trend.